A container for a two-component medicament, configured in such a manner that, when a cap is turned in the direction of opening the container body to administer eye drops, etc., the cap can be removed without causing a nozzle cap and the container body to become loose relative to each other. A nozzle cap (2) configured in such a manner that a small-diameter annular section (14) on which upper-stage...

The present invention discloses novel uses of specific menthol-derivative compounds of Formula 1, and compositions thereof, for methods of providing oral and systemic health care benefits, and methods of up-regulating or down-regulating periodontal disease metabolites: wherein, X is an oxygen atom or an NH radical; and R is an unsubstituted or substituted aryl or aliphatic radical. In some embodim...

A pharmaceutical composition for treating or ameliorating mucocutaneous, ocular toxicities, or side effects induced by blocking cellular growth and survival signal transduction pathways. The composition comprises an effective amount of a histone deacetylase inhibitor and a pharmaceutically acceptable carrier, salt or solvate thereof, wherein the cell growth and survival signal transduction pathway...

The present invention includes oral care compositions and methods for inhibiting growth and formation of oral biofilms by quorum sensing inhibition and/or bactericidal activity. In some embodiments, the present invention discloses an oral care composition including a therapeutically effective amount of at least one carbonate compound of formula 1 and at least one excipient: wherein, R1 and R2 are ...

The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effecti...

The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effecti...

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

It is desired to provide a pharmaceutical composition showing good dissolution, comprising a compound of formula (I), a pharmacologically acceptable salt or a solvate thereof, useful as a prevention/treatment agent of thrombotic diseases with the inhibition of activated blood coagulation factor X (FXa). The present invention is related to a solid pharmaceutical composition comprising a compound of...

Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

A pharmaceutical composition comprising quinagolide for the treatment and/or prevention of endometriosis.

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carr...

The present invention pertains to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof, or 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof, for the treatment of ophthalmologic disorders me...

The present invention pertains to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof, or 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoro-methyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof, for the treatment of disorders mediated by alpha...

Disclosed is a pharmaceutical composition for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of a claudin in a mammalian subject using the same fatty...

This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof.

Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.

The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.

A plant extract comprising one or more statins and being substantially free of polar compounds that affect pharmacokinetics of a drug in a subject is provided. Also provided is a method of preparing an extract comprising the step of removing polar compound that affect pharmacokinetics of a drug in a subject from a plant material containing one or more statins.

The present invention relates to a new use of compound. The present invention separates and purifies extract of Antrodia cinnomomea to obtain 4-hydroxy-2, 3-dimethoxy-6-methy-5(3, 7, 11-trimethyl-dodeca-2, 6, 10-trienyl)-cyclohex-2-enone. The cyclohexenone compound is useful in suppressing growth of tumor cell of pancreatic cancer and is applicable to a pharmaceutical composition that suppresses t...

The present invention relates to a new use of compound. The present invention separates and purifies extract of Antrodia cinnomomea to obtain 4-hydroxy-2, 3-dimethoxy-6-methy-5(3, 7, 11-trimethyl-dodeca-2, 6, 10-trienyl)-cyclohex-2-enone. The cyclohexenone compound is useful in suppressing growth of tumor cell of osteosarcoma and is applicable to a pharmaceutical composition that suppresses the gr...